Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
https://link.springer.com/content/pdf/10.1007/s00262-020-02577-w.pdf
Reference76 articles.
1. Freedman A (2018) Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol 93:296–305. https://doi.org/10.1002/ajh.24937
2. Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15:424–435. https://doi.org/10.1016/S1470-2045(14)70027-0
3. Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the prima study. J Clin Oncol 37:2815–2824. https://doi.org/10.1200/JCO.19.01073
4. Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331–1344. https://doi.org/10.1056/NEJMoa1614598
5. Casulo C, Nastoupil L, Fowler NH et al (2017) Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol Off J Eur Soc Med Oncol 28:2094–2106. https://doi.org/10.1093/annonc/mdx189
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Immunogenic Cell Death in Hematological Malignancy Therapy;Advanced Science;2023-02-23
2. Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC;Frontiers in Immunology;2023-01-17
3. Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect;International Journal of Molecular Sciences;2021-11-15
4. Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy;Journal of Translational Medicine;2021-09-20
5. An analysis of genetic targets for guiding clinical management of follicular lymphoma;Expert Review of Hematology;2020-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3